LYEL vs. BPMC, ROIV, RVMD, ELAN, VRNA, BBIO, GRFS, TLX, TGTX, and NUVL
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs. Its Competitors
Blueprint Medicines (NASDAQ:BPMC) and Lyell Immunopharma (NASDAQ:LYEL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Blueprint Medicines has a net margin of -13.19% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Blueprint Medicines' return on equity.
Blueprint Medicines received 540 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote.
Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.
66.1% of Lyell Immunopharma shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Blueprint Medicines has higher revenue and earnings than Lyell Immunopharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines presently has a consensus target price of $129.35, indicating a potential upside of 1.09%. Lyell Immunopharma has a consensus target price of $20.00, indicating a potential upside of 112.27%. Given Lyell Immunopharma's higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Blueprint Medicines.
In the previous week, Blueprint Medicines had 7 more articles in the media than Lyell Immunopharma. MarketBeat recorded 14 mentions for Blueprint Medicines and 7 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 0.66 beat Blueprint Medicines' score of 0.56 indicating that Lyell Immunopharma is being referred to more favorably in the news media.
Summary
Blueprint Medicines beats Lyell Immunopharma on 12 of the 19 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 6/12/2025 by MarketBeat.com Staff
